Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 9/2022

27-07-2022 | Prostate Cancer | Review Article

Recent topics of the clinical utility of PET/MRI in oncology and neuroscience

Authors: Yuji Nakamoto, Kazuhiro Kitajima, Akira Toriihara, Masatoyo Nakajo, Kenji Hirata

Published in: Annals of Nuclear Medicine | Issue 9/2022

Login to get access

Abstract

Since the inline positron emission tomography (PET)/magnetic resonance imaging (MRI) system appeared in clinical, more than a decade has passed. In this article, we have reviewed recently-published articles about PET/MRI. There have been articles about staging in rectal and breast cancers by PET/MRI using fluorodeoxyglucose (FDG) with higher diagnostic performance in oncology. Assessing possible metastatic bone lesions is considered a proper target by FDG PET/MRI. Other than FDG, PET/MRI with prostate specific membrane antigen (PSMA)-targeted tracers or fibroblast activation protein inhibitor have been reported. Especially, PSMA PET/MRI has been reported to be a promising tool for determining appropriate sites in biopsy. Independent of tracers, the clinical application of artificial intelligence (AI) for images obtained by PET/MRI is one of the current topics in this field, suggesting clinical usefulness for differentiating breast lesions or grading prostate cancer. In addition, AI has been reported to be helpful for noise reduction for reconstructing images, which would be promising for reducing radiation exposure. Furthermore, PET/MRI has a clinical role in neuroscience, including localization of the epileptogenic zone. PET/MRI with new PET tracers could be useful for differentiation among neurological disorders. Clinical applications of integrated PET/MRI in various fields are expected to be reported in the future.
Literature
1.
Brendle CB, Schmidt H, Fleischer S, Braeuning UH, Pfannenberg CA, Schwenzer NF. Simultaneously acquired MR/PET images compared with sequential MR/PET and PET/CT: alignment quality. Radiology. 2013;268(1):190–9.CrossRef
2.
Morita Y, Nogami M, Sakaguchi K, Okada Y, Hirota Y, Sugawara K, et al. Enhanced release of glucose into the intraluminal space of the intestine associated with metformin treatment as revealed by [18F]Fluorodeoxyglucose PET-MRI. Diabetes Care. 2020;43(8):1796–802.CrossRef
3.
Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, Larson PEZ, et al. PET/MRI: where might it replace PET/CT? J Magn Reson Imaging. 2017;46(5):1247–62.CrossRef
4.
Catalano OA, Lee SI, Parente C, Cauley C, Furtado FS, Striar R, et al. Improving staging of rectal cancer in the pelvis: the role of PET/MRI. Eur J Nucl Med Mol Imaging. 2021;48(4):1235–45.CrossRef
5.
Queiroz MA, Ortega CD, Ferreira FR, Nahas SC, Cerri GG, Buchpiguel CA. Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients. Eur J Nucl Med Mol Imaging. 2021;48(1):186–95.CrossRef
6.
Gassert FG, Rübenthaler J, Cyran CC, Rink JS, Schwarze V, Luitjens J, et al. 18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation. Eur J Nucl Med Mol Imaging. 2021;48(10):3268–76.CrossRef
7.
Morawitz J, Bruckmann NM, Dietzel F, Ullrich T, Bittner AK, Hoffmann O, et al. Comparison of nodal staging between CT, MRI, and 18F-FDG PET/MRI in patients with newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging. 2022;49(3):992–1001.CrossRef
8.
Husseini JS, Amorim BJ, Torrado-Carvajal A, Prabhu V, Groshar D, Umutlu L, et al. An international expert opinion statement on the utility of PET/MRI for imaging of skeletal metastases. Eur J Nucl Med Mol Imaging. 2021;48(5):1522–37.CrossRef
9.
Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, Vilstrup MH, Petersen H, Gerke O, et al. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules—a literature review. Eur J Nucl Med Mol Imaging. 2021;48(2):584–91.CrossRef
10.
Biondetti P, Vangel MG, Lahoud RM, Furtado FS, Rosen BR, Groshar D, et al. PET/MRI assessment of lung nodules in primary abdominal malignancies: sensitivity and outcome analysis. Eur J Nucl Med Mol Imaging. 2021;48(6):1976–86.CrossRef
11.
Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47(3):721–8.CrossRef
12.
Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F, et al. PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(3):859–73.CrossRef
13.
Ferraro DA, Becker AS, Kranzbuhler B, Mebert I, Baltensperger A, Zeimpekis KG, et al. Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. Eur J Nucl Med Mol Imaging. 2021;48(10):3315–24.CrossRef
14.
Bodar YJL, Zwezerijnen BGJC, Van der Voorn PJ, Jansen BHE, Smit RS, Kol SQ, et al. Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. Eur J Nucl Med Mol Imaging. 2022;49(5):1731–42.CrossRef
15.
Solari EL, Gafita A, Schachoff S, Bogdanović B, Asiares AV, Amiel T, et al. The added value of PSMA PET/MR radiomics for prostate cancer staging. Eur J Nucl Med Mol Imaging. 2022;49(2):527–38.CrossRef
16.
Linder T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22.CrossRef
17.
Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820–32.CrossRef
18.
Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48(1):73–86.CrossRef
19.
Zhang X, Song W, Qin C, Liu F, Lan X. Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas. Eur J Nucl Med Mol Imaging. 2021;48(8):2635–41.CrossRef
20.
Backhaus P, Gierse F, Burg MC, Buther F, Asmus I, Dorten P, et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging. 2022;49(6):1822–32.CrossRef
21.
Romeo V, Clauser P, Rasul S, Kapetas P, Gibbs P, Baltzer PAT, et al. AI-enhanced simultaneous multiparametric 18 F-FDG PET/MRI for accurate breast cancer diagnosis. Eur J Nucl Med Mol Imaging. 2022;49(2):596–608.CrossRef
22.
Papp L, Spielvogel CP, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B, et al. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI. Eur J Nucl Med Mol Imaging. 2021;48(6):1795–805.CrossRef
23.
Wang YJ, Baratto L, Hawk KE, Theruvath AJ, Pribnow A, Thakor AS, et al. Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure. Eur J Nucl Med Mol Imaging. 2021;48(9):2771–81.CrossRef
24.
Chen KT, Toueg TN, Koran MEI, Davidzon G, Zeineh M, Holley D, et al. True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation. Eur J Nucl Med Mol Imaging. 2021;48(8):2416–25.CrossRef
25.
Pozaruk A, Pawar K, Li S, Carey A, Cheng J, Sudarshan VP, et al. Augmented deep learning model for improved quantitative accuracy of MR-based PET attenuation correction in PSMA PET-MRI prostate imaging. Eur J Nucl Med Mol Imaging. 2021;48(1):9–20.CrossRef
26.
Guo K, Wang J, Wang Z, Wang Y, Cui B, Zhao G, et al. Morphometric analysis program and quantitative positron emission tomography in presurgical localization in MRI-negative epilepsies: a simultaneous PET/MRI study. Eur J Nucl Med Mol Imaging. 2022;49(6):1930–8.CrossRef
27.
Liu F, Ruan W, Deng X, Song Y, Song W, Hu F, et al. Efficacy of delayed 18F-FDG hybrid PET/MRI for epileptic focus identification: a prospective cohort study. Eur J Nucl Med Mol Imaging. 2021;48(1):293–301.CrossRef
28.
Hu X, Sun X, Hu F, Liu F, Ruan W, Wu T, et al. Multivariate radiomics models based on 18F-FDG hybrid PET/MRI for distinguishing between Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2021;48(11):3469–81.CrossRef
29.
Tiepolt S, Becker GA, Wilke S, Cecchin D, Rullmann M, Meyer PM, et al. (+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand-results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2021;48(3):731–46.CrossRef
30.
Lai TH, Toussaint M, Teodoro R, Dukić-Stefanović S, Gündel D, Ludwig FA, et al. Improved in vivo PET imaging of the adenosine A2A receptor in the brain using [18F]FLUDA, a deuterated radiotracer with high metabolic stability. Eur J Nucl Med Mol Imaging. 2021;48(9):2727–36.CrossRef
Metadata
Title
Recent topics of the clinical utility of PET/MRI in oncology and neuroscience
Authors
Yuji Nakamoto
Kazuhiro Kitajima
Akira Toriihara
Masatoyo Nakajo
Kenji Hirata
Publication date
27-07-2022
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 9/2022
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01780-2

Other articles of this Issue 9/2022

Annals of Nuclear Medicine 9/2022 Go to the issue

Letter to the Editor

The safe handling of 211At compounds

Original Article

Comparison of skeletal segmentation by deep learning-based and atlas-based segmentation in prostate cancer patients

Letter to the Editor

Response to the letter to the editor

Original Article

Crossed cerebellar diaschisis-related supratentorial hemodynamic and metabolic status measured by PET/MR in assessing postoperative prognosis in chronic ischemic cerebrovascular disease patients with bypass surgery

Review Article

Advances in positron emission tomography tracers related to vascular calcification

Original Article

Unusual perfusion patterns on perfusion-only SPECT/CT scans in COVID-19 patients